Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Germany-based Jomaa Pharma, a biopharmaceutical company dedicated to malaria chemotherapy, and Medicines for Malaria Venture (MMV), a not-for-profit research foundation, , have signed a memorandum of understanding (MoU) to jointly develop fosmidomycin as part of non-artemisinin based combination therapy (NACT) to treat acute Plasmodium falciparum malaria.
Subscribe to our email newsletter
Fosmidomycin is a molecule that possesses antimalarial and antibacterial activity.
The co-development project follows reports of the emergence of artemisinin resistance on the Thai-Cambodian border.
Jomaa Pharma MD David Hutchinson said that a concept study of fosmidomycin coupled with piperaquine was being planned for later this year in Thailand which will be followed by Phase II studies in children and toddlers in sub-Saharan Africa.
"We are also collaborating with the European and Developing Countries Clinical Trials Partnership (EDCTP) to develop NACT products based on fosmidomycin under an existing grant," Hutchinson said.
MMV CEO Tim Wells said they are very interested in working with Jomaa Pharma and the opportunity this gives us to develop fosmidomycin as a novel antimalarial agent.